Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1 Pancreatic Neoplasms 1 Gastric Adenocarcinoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Capecitabine 77 pembrolizumab 70 Oxaliplatin 68 Cisplatin 56 Fluorouracil 52 Paclitaxel 41 Trastuzumab 36 Nivolumab 35 Leucovorin 27 Docetaxel 27 Irinotecan 22 Ramucirumab 20 Gemcitabine 15 Bevacizumab 15 S 1 (combination) 14 Carboplatin 13 atezolizumab 12 apatinib 12 fludarabine 11 Cyclophosphamide 11 tislelizumab 10 Drug Therapy 10 Injections 8 130-nm albumin-bound paclitaxel 8 trastuzumab deruxtecan 7 durvalumab 7 Ipilimumab 7 Folfox protocol 7 Albumin-Bound Paclitaxel 7 titanium silicide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Stomach Neoplasms × andecaliximab × Clear all

NCT02545504 2020-05-26

GAMMA-1

Gilead Sciences

Phase 3 Completed

432 enrolled 19 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡